Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
VANCOUVER, BC, Feb. 18, 2025 (GLOBE NEWSWIRE) -- AMERICAN SALARS LITHIUM INC. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN: A3E2NY ) announces that it has entered into
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
10:41am, Friday, 14'th Feb 2025
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
09:53pm, Thursday, 13'th Feb 2025
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
06:30pm, Thursday, 13'th Feb 2025
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall S
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Thursday, 13'th Feb 2025
Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.52 per share a year ago.
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
04:01pm, Thursday, 13'th Feb 2025
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
04:30pm, Thursday, 06'th Feb 2025
NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
11:31am, Thursday, 06'th Feb 2025
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
08:00am, Wednesday, 05'th Feb 2025
Modified intent-to-treat group demonstrated +22.7 point (p
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 17'th Jan 2025
NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
02:05pm, Wednesday, 15'th Jan 2025
In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc RARE.
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
11:00am, Sunday, 12'th Jan 2025
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
11:25am, Tuesday, 07'th Jan 2025
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 06'th Jan 2025
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
First and only medicine approved in the EU for paediatric patients aged 6-months to 5 years old with HoFH, an ultrarare, inherited form of high cholesterol First and only medicine approved in the EU f
